MIRM · Mirum Pharmaceuticals, Inc.

Mirum delivered strong revenue growth in Q1 FY2026, with product revenue reaching $159.9 million, up 43.3% from $111.6 million in the prior year quarter. This increase reflects expanding commercialization of approved medicines, though management notes quarterly fluctuations may occur due to large periodic orders from partners like Takeda and distributors. We expect total product sales to continue rising annually, supported by variable costs scaling with volume such as royalties and inventory.

Despite revenue momentum, operating income swung to a substantial loss of -$789.5 million from -$15.2 million YoY, yielding an operating margin of -493.8%. This sharp deterioration stems from expenses outpacing top-line growth, consistent with management's outlook for rising selling, general, and administrative costs to support U.S. commercialization efforts. Prior and expected future net losses continue adversely affecting stockholders' equity and working capital, underscoring the capital-intensive nature of biopharma scaling.

Net income followed suit at -$790.2 million versus -$14.7 million last year, with diluted EPS at -$13.43 compared to -$0.30. The widened losses highlight the period's investment phase, where operational scaling and strategic moves like the Bluejay acquisition influenced working capital dynamics, including higher accounts receivable from sales growth and prepaid assets from acquired items.

Management commentary points to cost of sales increases driven by royalties on net sales of key medicines under licensing agreements and supply chain support, aligning with expectations for variable costs to rise with product volumes. These dynamics position Mirum in a heavy investment phase to fuel commercial momentum, though they elevate cash utilization and liquidity risks amid ongoing losses.